INDEPENDENT INTELLIGENCE
LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Immunic, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERIMUX
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / IMUX COVERAGE

What’s moving Immunic, Inc. now

Current reporting with the operating signal separated from the noise.

01
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

The story matters when it changes Immunic, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Immunic, Inc. to Participate in Investor and Scientific Conferences in February

Immunic, Inc. to Participate in Investor and Scientific Conferences in February

The story matters when it changes Immunic, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

The story matters when it changes Immunic, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Earnings Call Transcript

Immunic, Inc. (IMUX) CEO Daniel Vitt on Q2 2020 Results

The story matters when it changes Immunic, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Immunic, Inc. to Participate in Investor and Scientific Conferences in June

Immunic, Inc. to Participate in Investor and Scientific Conferences in June

The story matters when it changes Immunic, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest IMUX filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-13 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-13 · Period 2025-09-30SEC ↗10-K/AAnnual financial reportFiled 2026-04-22 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-14 · Period 2026-07-14SEC ↗8-KMaterial company eventFiled 2026-07-06 · Period 2026-06-29SEC ↗8-KMaterial company eventFiled 2026-06-29 · Period 2026-06-29SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-05-29 · Period 2026-06-29SEC ↗SCHEDULE 13GOfficial SEC filingFiled 2026-08-04SEC ↗
EARNINGS / QUARTERLY TRACKER

Immunic, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.